Alumis Surges 400% as Cormorant Adds $8M; DeepValue Flags Limited Upside

What happened

Alumis stock has skyrocketed ~400% to $24.17 following strong Phase 3 psoriasis data for envudeucitinib, with insider Cormorant Asset Management purchasing another $8 million last quarter. Despite the optimism, the DeepValue master report assigns a 'Potential Sell' rating, noting the stock already prices in successful approval and meaningful lupus optionality while facing fierce once-daily competition and a ~$400M annual cash burn. The report's base case of $24 offers little upside from current levels, with bear scenario at $15 and bull at $32, implying asymmetrical downside risk over 6–18 months. Insider buying, including coordinated purchases by Foresite entities, has been aggressive but may reflect structured arrangements rather than pure conviction. The near-term catalyst calendar is skewed toward risk (detailed safety, once-daily formulation clarity, lupus data) rather than new positive surprises.

Implication

The stock's valuation already discounts a smooth psoriasis approval and multi-indication franchise, leaving limited upside. Key triggers to re-evaluate: entry below $17 (attractive entry per DeepValue), positive lupus Phase 2b data in Q3 2026, or de-risking of once-daily envudeucitinib. Absent these, the risk/reward is unattractive given competition from once-daily orals and high cash burn.

Thesis delta

Insider buying by Cormorant and others signals confidence, but DeepValue's fundamental analysis suggests the market has fully priced in success, leaving no margin of safety. The thesis shifts from 'buying with insiders' to 'fading momentum' – the crowded bullish consensus and recent equity raise create downside vulnerability. Investors should prioritize valuation discipline over celebrity insider moves.